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Objectives: The Medical Outcomes Study HIV Health
Survey (MOS-HIV) is frequently used in HIV clinical
trials; however, scores generated from the MOS-HIV are
not suited for cost-effectiveness analyses as they do not
assign utility values to health states. Our objective was
to estimate and externally validate several mapping algo-
rithms to predict Health Utilities Index Mark 3 (HUI3)
and EQ-5D-3L utility values from the MOS-HIV.
Methods: We developed and validated mapping algo-
rithms using data from two HIV clinical trials. Data from
the first trial (n = 367) formed the estimation data set for
the HUI3 (4,610 observations) and EQ-5D-3L (4,662
observations) mapping algorithms; data from the second
trial (n = 168) formed the HUI3 (1,135 observations) and
EQ-5D-3L (1,152 observations) external validation data
set. We compared ordinary least squares (OLS) models
of increasing complexity with the more flexible two-part,
beta regression, and finite mixture models. We assessed
model performance using mean absolute error (MAE)
and mean squared error (MSE). Results: The OLS model
that used MOS-HIV dimension scores along with squared
terms gave the best HUI3 predictions (mean observed
0.84; mean predicted 0.80; MAE 0.0961); the finite mix-
ture model gave the best EQ-5D-3L predictions (mean
observed 0.90; mean predicted 0.88; MAE 0.0567). All
models produced higher prediction errors at the lower
end of the HUI3 and EQ-5D-3L score ranges (\0.40).
Conclusions: The proposed mapping algorithms can be
used to predict HUI3 and EQ-5D-3L utility values from
the MOS-HIV, although greater error may pose a problem
in samples where a substantial proportion of patients are
in poor health. These algorithms may be useful for esti-
mating utility values from the MOS-HIV for cost-effective-
ness studies when HUI3 or EQ-5D-3L data are not avail-
able. Key words: AIDS; HIV; health-related quality of
life; health utilities; preference-based measures; MOS-
HIV; HUI3; EQ-5D; mapping. (MDM Policy & Practice
XXXX:XX:xx–xx)
Since the advent of modern antiretroviral therapy(ART), HIV has transformed into a chronic and
manageable disease.1–3 Coupled with the ongoing
release of new effective treatments,4–6 the goal of
therapy is to extend survival to levels near that of
the general population while maximizing quality of
life.7 To that end, researchers have used health sta-
tus instruments to assess HIV’s impact on function-
ing and quality of life, thus adding useful informa-
tion to clinical trials.8–13
The Medical Outcomes Study HIV Health Survey
(MOS-HIV) is one of the most frequently used
instruments in HIV quality-of-life research and is
well-established in terms of its reliability, construct
validity, and responsiveness.11,14,15 However,
MOS-HIV scores are not suited for calculating
quality-adjusted life years (QALYs) for use in cost-
effectiveness analysis (CEA) as the instrument does
not assign preference-based values to health states.
The QALY, generated from preference-based values
or utilities, provides a generic health outcome com-
parable across disease areas and is the preferred mea-
sure where CEA is used to inform national health
care resource allocation.16 In practice, preference-
based measures, such as the Health Utilities Index
Mark 3 (HUI3) or EQ-5D-3L, are infrequently
included along with other quality-of-life instruments
in trials, thus limiting the ability to assess the cost-
effectiveness of HIV interventions from such data.
Mapping, sometimes referred to as cross-walking,
may help researchers who wish to conduct CEAs,
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but are lacking utility values. The fundamental
assumption underlying this approach is that the
impacts on quality of life captured by the disease-
specific health status measure overlap with those
captured in the target utility measure. Mapping
algorithms can be derived by specifying a regression
model that uses the ‘‘target’’ utility measure as the
dependent variable and includes the disease-spe-
cific health status measure as an independent vari-
able. Parameters from this regression can then be
used to predict utility values based on the health
status measure gathered in a different population.17
Bansback and others,18 for example, developed sev-
eral models in which either the preference-based
EQ-5D-3L or Short Form-6D (SF-6D) were regressed
on the domain scores from the Health Assessment
Questionnaire Disability Index (HAQ-DI) in patients
with rheumatoid arthritis (RA). These algorithms
were then applied to studies that measured the
HAQ-DI but not utility values. Predicted utility val-
ues were used to assess the cost-effectiveness of
numerous interventions in RA.19 Similar mappings
have been developed using data from patients with
Parkinson’s disease,20 cystic fibrosis,21 depres-
sion,22 and from other cohorts.17,23
Huang and others24 mapped the MOS-HIV onto
the EQ-5D-3L, but to our knowledge, there are no
studies that map the MOS-HIV onto the HUI3.
Our objective was to estimate and validate map-
ping algorithms to predict HUI3 and EQ-5D-3L util-
ity values from the MOS-HIV in patients with HIV.
We built upon the work by Huang and others24 by
comparing a series of ordinary least squares (OLS)
models of increasing complexity with two-part, beta
regression-based, and finite mixture models25 and
assessing model performance using external valida-
tion tests.
METHODS
Data
Data from the VA Cooperative Studies Program
Options in Management with Antiretrovirals (OPTIMA)
trial formed the estimation data sets. The design and
main findings have been reported previously.26,27
Briefly, OPTIMA was a 2 3 2 factorial randomized
clinical trial that randomized 368 multidrug-resistant
HIV-infected patients to an intended 12-wk treat-
ment interruption or no interruption and to ART
intensification (five or more antiretroviral drugs) or
standard ART (four or fewer antiretroviral drugs).
Patients were eligible for enrollment if they had evi-
dence of serial treatment failure or antiretroviral
resistance, were receiving ART, had low CD4 counts
(300 cells/mm3), and had HIV-1 viral load levels
5,000 copies/mL. The OPTIMA study was con-
ducted at more than 70 clinical sites throughout the
United Kingdom, Canada, and the United States
between 2001 and 2006, with a median follow-up
time of 3.2 years. We collected health status (MOS-
HIV) and health-related quality-of-life (HRQoL) data
(HUI3 and EQ-5D-3L) at baseline; weeks 6 and 12;
and every 12 weeks thereafter.
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Infection (MAINTAIN) study formed the external
validation data sets for the HUI3 and EQ-5D-3L
mapping models.28,29 MAINTAIN was a multicenter
randomized double-blind clinical trial evaluating
micronutrient supplementation that randomized
171 HIV-infected patients to receive either a micro-
nutrients and antioxidants preparation or multivita-
mins and minerals for 2 years. Participants were eli-
gible if they were asymptomatic adults with
baseline CD4 counts 375 and 750 mm3 and were
ART naı¨ve. MAINTAIN, which enrolled patients
between 2009 and 2012, was conducted at 16 sites
throughout Canada. Follow-up concluded in 2014.
Data on HRQoL, including MOS-HIV, HUI3, and
EQ-5D-3L, were collected at baseline and at quar-
terly intervals through study termination (week 96).
While there are several recommendations cur-
rently available for use,30,31 we chose to follow the
MApping onto Preference-based measures reporting
Standards (MAPS).32,33 The US Department of
Veterans Affairs, the UK Medical Research Council,
and the Canadian Institutes for Health Research
approved the design and conduct of the OPTIMA
clinical trial. The Canadian Institutes for Health
Research approved the use of MAINTAIN data for
the purposes of this study. None of the agencies
listed had a role in the writing of this article. The
authors have no competing interests.
Instruments
The MOS-HIV is a 30-item descriptive disease-
specific questionnaire assessing 10 dimensions of
health focused on capturing health impairments
that are unique to patients with HIV.15 The sub-
scales for the dimensions range from 0 to 100 with
higher scores indicating better health.
The HUI3 includes 17 questions used to calculate
8 attributes each with 5 or 6 levels for a total of
972,000 possible health states.34 Preference weights
were estimated with valuation data from a random
sample of the general population in Hamilton,
Ontario, Canada, and were used in a multiplicative
model to compute utility values ranging from 20.36
to 1. For all preference-based instruments used in the
primary and validation data sets, a score of 0 is equiv-
alent to death and a score of 1 represents full health.
The EQ-5D-3L is a five-item questionnaire cover-
ing five dimensions of health.35 Each dimension
contains three levels for a total of 245 possible
health states. Value sets for the EQ-5D-3L have been
developed for many countries, which enable the
estimation of an index for each possible health
state.36 We used Shaw and colleagues’37 US
population–based EQ-5D-3L preference weights to
calculate the EQ-5D-3L index (range: 20.11 to 1).
All instruments were in English and paper-based.
In order to assess conceptual overlap between the
MOS-HIV and either the HUI3 or EQ-5D-3L, we dia-
grammed the overlap between HUI3 or EQ-5D-3L
domains and MOS-HIV dimensions (Figure 1) and
analyzed Spearman correlations between HUI3 or
EQ-5D-3L domains and MOS-HIV dimensions or
summary scores (Appendix Table 1).
Statistical Analysis
All surveys with complete responses to the HUI3
or EQ-5D-3L were included. Per developer guide-
lines, we substituted missing MOS-HIV values with
mean values if more than 2 items in a subscale were
missing and if the number of missing items was
50%.15 Given that the relationship between the
utility measure (either the HUI3 or EQ-5D-3L) and
the MOS-HIV is unlikely to change over time, we
pooled data from all time points for the estimation
or external validation data sets. We calculated
robust cluster-corrected standard errors to take into
account multiple observations per subject. All anal-
yses were performed using STATA version 13.1
(StataCorp, College Station, TX) and SAS 9.4 (SAS
Institute, Cary, NC).
We reported descriptive statistics as means (stan-
dard deviation [SD]) for continuous data and per-
centages for categorical data, unless noted other-
wise, by study.
We applied four different statistical techniques
in building our mapping models, OLS, two-part
regression, beta regression, and finite mixture, to
map to either the HUI3 or EQ-5D-3L index scores.
OLS is the most common mapping approach17,23
and has been shown to predict mean values with
reasonable accuracy. We evaluated several OLS
regression models. Models 1a and 2a: HUI3 or EQ-
5D-3L index regressed on 10 MOS-HIV dimensions
of health; Models 1b and 2b: same as 1a and 2a with
the addition of squared terms; Models 1c and 2c:
same as 1b and 2b with the addition of all possible
two-way interaction terms. We added squared terms
to address potential nonlinear associations between
MOS-HIV dimension scores and either the HUI3 or
EQ-5D-3L utility values. Interaction terms were sub-
sequently added given evidence that dimensions
are not additive.34
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Two-part models have also been used in previous
mapping studies38 as a way to accommodate those
with EQ-5D-3L (HUI3) scores of one (perfect health)
and any differences they have compared to those
with less than perfect health. Models 1d and 2d use a
logistic regression to estimate the probability of full
health, as well as an OLS regression using the 10
MOS-HIV dimensions of health to predict the EQ-5D-
3L (HUI3) index score for those in less than full
health. The predicted EQ-5D-3L (HUI3) index score is
the product of the predicted probability from the
logistic regression and the predicted expected value
from the OLS regression. We used the STATA twopm
module, which required that we transform our index
values (e.g., Y = 1 2 EQ-5D-3L) prior to running the
models.
Basu and Manca25 explored several regression
models based on the beta distribution. The authors
sought to address the characteristics typical of
HRQoL data, including negative skew, upper and
lower bounds to observed values (truncated sup-
ports), and spikes at 1 (perfect health). They found
that one- and two-part beta regression models are
more robust in estimating covariate effects than
OLS. The HUI3 and the EQ-5D-3L data possess
many of these typical characteristics including long
left tails, an upper bound at 1, and a lower bound
determined by tariffs. As such, we evaluated beta
regression based on quasi likelihood estimation (Beta
QMLE) using the STATA program betafit developed
by Basu and Manca in which we used transformed
HUI3 or EQ-5D-3L index scores regressed on 10
MOS-HIV dimensions of health (Models 1e and 2e;
transformation and prediction methods described in
Appendix Table 2; full method detailed in Basu and
Manca25).
Finite mixture models have been used to address
the often multimodal distribution of utilities. These
types of models allow for unobserved heterogeneity
for different classes of individuals by assuming a
combination of two or more distributions mixed
with unknown probabilities. Previous studies have
used finite mixture models to map the Roland
Morris Questionnaire and Parkinson’s Disease
Questionnaire to the EQ-5D-3L20,39 and estimate the
HUI3.40 Coca Perraillon and others mapped the SF-
12 to the EQ-5D-3L and found that finite mixture
models outperformed OLS and two-part models.
The authors noted that finite mixture model predic-
tions were best at the tails of the distribution.41 We
used the authors’ zicen STATA module to map the
10 MOS-HIV dimensions onto the EQ-5D-3L. Model
Figure 1 Conceptual overlap between the MOS-HIV dimensions and HUI3 or EQ-5D-3L domains.
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2f characterizes the EQ-5D-3L index as a mixture of
three distributions: two censored normal (Tobit)
distributions and a third distribution with a mass of
values at 1 (perfect health). We attempted to map
the 10 dimensions onto the HUI3, but our finite
mixture models, either with three or two classes,
would not converge. Model 1f maps the physical
health summary and mental health summary scores
onto the HUI3 using a mixture of two distributions:
one censored normal distribution and one with a mass
of values at 1 (perfect health). Similar to our two-part
models, we transformed the EQ-5D-3L and HUI3 val-
ues prior to running the models (e.g., Y = 12 HUI3).
We fit our models using the OPTIMA data set as
our estimation cohort. The models were also
applied to the MAINTAIN data set to explore the
external validity of the algorithms. Parameters from
these models were then applied to the MOS-HIV
values to predict the utility values that would have
been estimated by either HUI3 or EQ-5D-3L. We com-
pared the predicted values to the actual values
obtained in the MAINTAIN trial. We explored the
models’ goodness of fit by examining the mean and
range of predicted values. We also reviewed the dif-
ference between predicted values and the values
observed in the OPTIMA and MAINTAIN trials by
reporting the mean squared error (MSE), which is the
mean of squared differences between observed and
predicted utility value scores, and mean absolute
error (MAE), which is the mean of the absolute differ-
ences between observed and predicted utility value
scores. A priori, we used MAE to choose the preferred
model. We also reviewed the pattern of MAE across
the range of utility values for HUI3 and EQ-5D-3L by
reporting predicted values for subsets of the indices.
RESULTS
Study Cohort
OPTIMA collected 4,783 HUI3 surveys, 4,852
EQ-5D-3L surveys, and 4,787 MOS-HIV surveys
over a maximum of 6.25 years (median, 3.2 years)
for 367 patients. One patient did not complete any
HRQoL surveys. Of those surveys, 4,610 included
data on both the HUI3 and all MOS-HIV dimensions
of health, while 4,662 had data on both the EQ-5D-
3L and all MOS-HIV dimensions. MAINTAIN col-
lected 1,163 HUI3 surveys, 1,182 EQ-5D-3L surveys,
and 1,163 MOS-HIV surveys over 30.7 months (med-
ian, 10.9 months) for 168 patients. Of those, 1,135
included data on both the HUI3 and all 10 MOS-HIV
dimensions of health; 1,152 had data on both
the EQ-5D-3L and all MOS-HIV dimensions. Three
patients failed to complete any HRQoL surveys.
OPTIMA subjects, who made up the estimation
sample, were on average older (48 years v. 38 years),
included more men (98% v. 83%), were more racially
diverse (51% non-White v. 29%), and had a lower
median CD4+ cell count (108 v. 494 cells/mm3) than
MAINTAIN subjects (external validation sample).
There were also differences in HRQoL data
recorded in the estimation and validation data sets
(Table 1). For example, the MOS-HIV score for phys-
ical functioning was 64.8 (SD 28.3) in the OPTIMA
cohort versus 88.2 (SD 23.2) in the MAINTAIN
cohort. Preference-based scores also varied, with a
mean HUI3 index score of 0.62 (SD 0.31) in OPTIMA
and 0.84 (SD 0.21) in the MAINTAIN data set. The
mean EQ-5D-3L index score was 0.77 (0.19) in the
OPTIMA data set and 0.90 (SD 0.12) in the
MAINTAIN data set. As expected, EQ-5D-3L scores
were skewed at the upper bound; approximately
22% of OPTIMA surveys and 51% of MAINTAIN
surveys had scores of 1.
Model Estimation
Results from all models are shown in Appendix
Tables 3 and 4; results from our preferred models
are shown in Table 2. Across the OLS (1a-1c), two-
part (1d), and beta QMLE (1e) HUI3 models,
improvements in almost all MOS-HIV dimension
scores were significantly associated with improve-
ments in preference-based quality of life. Squared
terms for pain and social functioning in Models 1b
and 1c are always negative and significant (P \
0.05); several interaction terms in Model 1c are also
significant with mixed signs.
Most main coefficients in the EQ-5D-3L Models
2a (OLS), 2d (two-part), 2e (Beta QMLE) had the
expected sign and were significant, indicating that
improvements in MOS-HIV dimensions were asso-
ciated with higher EQ-5D-3L utility value scores.
Across all EQ-5D-3L models, improvements in pain
and physical functioning were significantly associ-
ated with an improvement in EQ-5D-3L index score.
As with the HUI3 models, squared terms for pain
and social functioning in Models 2b and 2c are neg-
ative and significant, as is quality of life (P\ 0.05);
some interaction terms in Model 2c are significant.
Model Validation and Performance
All models performed similarly in their ability to
predict the mean observed HUI3 utility value score
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in the validation sample 0.84 (SD 0.21) with means
of 0.80 or 0.81 (SD 0.18–0.21) (Table 3). Most mod-
els predicted negative values with Model 1c pre-
dicting the value closest to the observed minimum
value (20.05 v. 20.14). Ranked by MSE and MAE,
the OLS model with squared terms (1b) gave the
best predictions (MSE 0.0197 and MAE 0.0961).
Also, all models were similar in their ability to
predict mean EQ-5D-3L in the external validation
data set (0.90, SD 0.12) with means of 0.87 or 0.88
(SD 0.09–0.13) (Table 4). The finite mixture model
(2f) came closest to predicting the lowest observed
EQ-5D-3L utility value score of 0.20 with a lowest
predicted score of 0.31. The two-part model (2d),
along with the finite mixture model (2f), came
closest to predicting the maximum EQ-5D-3L utility
value score without exceeding 1. The model with
the lowest MSE (0.0083) was the OLS model with
squared and interaction terms (2c). If ranked by
MAE, however, the finite mixture model (2f) gave
the best predictions (0.0567).
Mean absolute error, regardless of model, was
much greater at the lower ends of the utility mea-
sure ranges, which indicate poorer health, than at
the upper ends (Figure 2a and b). For example, in
the Beta QMLE model, for HUI3 utility value scores
below 0.40, the mean absolute errors in the external
validation sample ranged from 0.21 to 0.31. An
observed HUI3 score of, for example, 0.40, might
have a complementary predicted score of anywhere
Table 1 Health-Related Quality-of-Life Scores for the OPTIMA Estimation Sample and MAINTAIN
External Validation Sample
OPTIMA Estimation Set MAINTAIN External Validation Set
Medical Outcomes Study HIV Health Survey
Number of surveys 4,787 1,161
Mean dimensions (SD)
General health perception 47.8 (23.9) 68.1 (22.1)
Pain 59.4 (28) 77.3 (23.9)
Quality of life 60.9 (20.9) 71.6 (20.3)
Role functioning 44.8 (45.7) 86.9 (30.3)
Social functioning 70.0 (28.8) 88.8 (20.2)
Energy/fatigue 51.4 (24.1) 63.5 (19.9)
Mental health 66.7 (21.3) 71.8 (18.9)
Health distress 70.9 (25.6) 79.6 (23.3)
Cognitive functioning 74.4 (23.2) 82.7 (19.3)
Physical functioning 64.8 (28.3) 88.2 (23.2)
Health Utilities Index Mark 3 Index
Number of surveys 4610 1135
Mean (SD) 0.62 (0.31) 0.84 (0.21)
Median [IQR] 0.69 [0.42–0.88] 0.92 [0.78–0.97]
Scores\0 (%) 4.6 0.7
Scores 0 to 0.20 (%) 7.8 1.1
Scores 0.20 to 0.40 (%) 11.3 3.6
Scores 0.40 to 0.60 (%) 17 7
Scores 0.60 to 0.80 (%) 21.8 14.4
Scores 0.80 to 1 (%) 37.5 73.2
Scores at upper bound of 1 (%) 6.2 20.2
EQ-5D-3L Index
Number of surveys 4662 1152
Mean (SD) 0.77 (0.19) 0.90 (0.12)
Median [IQR] 0.80 [0.71–0.84] 1.00 [0.83–1]
Scores\0.40 (%) 7 0.5
Scores 0.40 to 0.60 (%) 9.1 3.1
Scores 0.60 to 0.80 (%) 38 19.6
Scores 0.80 to 1 (%) 45.9 76.7
Scores at upper bound of 1 (%) 21.7 51.1
Note: IQR = interquartile range.
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Table 2 Parameter Estimates for the Preferred Models Used to Estimate HUI3 Index (Model 1b) and EQ-5D-3L Index (Model 2f)
Model 2f—EQ-5D-3LFinite Mixture; s1 = .022626, s2 = .155041
Model 1b—HUI3; OLS EQ1 EQ2 IMLOGIT1 IMLOGITP2
b SE b SE b SE b SE b SE
Intercept 20.439103* 0.058571 0.26825464* .0036095 0.70584905* .0149963 11.076029* .5285108 16.555844* 0.6236399
MOS-HIV dimensions
General health perception 0.001869* 0.000630 20.000001813 .0000329 0.00016097 .0002595 20.00695022* .0030701 20.00862315* 0.0043556
Pain 0.007183* 0.000671 20.00030894* .0000255 20.00413961* .0002044 20.0406544* .0025694 20.06313058* 0.0036435
Quality of life 0.001779* 0.000816 20.00013865* .0000412 20.00091289* .0002921 20.00382105 .0040006 20.01298886* 0.0054761
Role functioning 0.000156 0.000417 20.00007279* .0000142 0.0010807* .0001904 20.00666376* .0014582 20.01995899* 0.0021132
Social functioning 0.003304* 0.000703 20.000005094 .000031 20.00082791* .0002063 20.00350141 .0035252 20.00687216 0.0042682
Energy/fatigue 0.002787* 0.000912 0.00002412 .0000382 0.00049648 .0002774 20.00635364 .0035594 20.01552923* 0.0048987
Mental health 0.002948* 0.001285 20.00029687* .0000455 20.00040869 .0003335 20.028013* .0045861 20.03206664* 0.0061638
Health distress 20.001440 0.000786 20.00004191 .0000363 20.00030816 .0002361 20.01162153* .0040871 20.0167202* 0.0050887
Cognitive functioning 0.003267* 0.001260 20.00010271* .0000353 0.00000712 .0002322 20.02148051* .004639 20.03952272* 0.0058227
Physical functioning 0.000591 0.000736 20.00017095* .0000292 20.00097572* .0002179 20.00523421* .0023961 20.02822543* 0.0035124
MOS-HIV squared dimensions
General health perception_sq 20.000015* 0.000006
Pain_sq 20.000037* 0.000005
Quality of life_sq 20.000005 0.000007
Role functioning_sq 0.000005 0.000004
Social functioning_sq 20.000020* 0.000006
Energy/fatigue_sq 20.000016* 0.000008
Mental health_sq 20.000012 0.000010
Health distress_sq 0.000008 0.000006
Cognitive functioning_sq 0.000006 0.000009
Physical functioning_sq 0.000004 0.000006
Note: HUI3 = Health Utilities Index Mark 3 survey; MOS-HIV = Medical Outcomes Study HIV Health Survey; OLS = ordinary least squares.
*P\ 0.05.
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between 0.19 and 0.61. In contrast, for HUI3 utility
scores above 0.40, the MAE ranged from 0.17 to
0.08. The Beta QMLE HUI3 mapping model per-
formed best (lowest MAE) at the lowest end of the
score ranges (\0); the finite mixture EQ-5D-3L
model performed best for those with EQ-5D-3L
scores\0.40.
Applying the Mapping Algorithm
We have illustrated how to calculate utility value
scores from the MOS-HIV by providing an example
below as well as examples in an online supplement.
Here we have calculated HUI3 scores based on the
parameter estimates from the HUI3 OLS+squared
Table 3 Performance of Mapping Models to Predict HUI3 Utilities From MOS-HIV Data
Model Mean SD Min Max MSE MAE
Estimation sample (n = 4,610)
Observed HUI3 0.62 0.31 20.35 1 — —
Model 1a. OLS 0.62 0.26 20.25 1.10 0.0304 0.1332
Model 1b. OLS (+ squared) 0.62 0.26 20.44 1.02 0.0283 0.1261
Model 1c. OLS (+ squared + interaction) 0.62 0.27 20.40 1.01 0.0271 0.1224
Model 1d. Two-part 0.62 0.26 20.25 1.07 0.0302 0.1315
Model 1e. Beta QMLE 0.62 0.27 20.24 0.95 0.0291 0.1277
Model 1f. Finite mixturea 0.63 0.26 20.18 1.14 0.0349 0.1431
External validation sample (n = 1,135)
Observed HUI3 0.84 0.21 20.14 1 — —
Model 1a. OLS 0.81 0.21 0.08 1.09 0.0215 0.1040
Model 1b. OLS (+ squared) 0.80 0.19 20.004 1.01 0.0197 0.0961
Model 1c. OLS (+ squared + interaction) 0.80 0.20 20.05 1.01 0.0206 0.0981
Model 1d. Two-part 0.81 0.21 0.08 1.05 0.0209 0.0993
Model 1e. Beta QMLE 0.80 0.18 20.003 0.95 0.0199 0.0988
Model 1f. Finite mixture 0.80 0.18 0.05 0.97 0.0209 0.1015
Note: HUI3 = Health Utilities Index Mark 3 survey; MOS-HIV = Medical Outcomes Study HIV Health Survey; MSE = mean squared error; MAE =
mean absolute error; OLS = ordinary least squares; Beta QMLE = beta regression based on quasi likelihood estimation.
aModel 1f maps the physical health summary (PHS) and mental health summary (MHS) scores onto the HUI3. A previous model which mapped the
10 MOS-HIV dimensions onto the HUI3 failed to converge.
Table 4 Performance of Mapping Models to Predict EQ-5D-3L Utilities From MOS-HIV Data
Model Mean SD Min Max MSE MAE
Estimation sample (n = 4,662)
Observed EQ-5D-3L 0.77 0.19 20.11 1 — —
Model 2a. OLS 0.77 0.14 0.33 1.03 0.0153 0.0917
Model 2b. OLS (+ squared) 0.77 0.15 0.19 0.98 0.0140 0.0892
Model 2c. OLS (+ squared + interaction) 0.77 0.15 0.20 1.01 0.0134 0.0872
Model 2d. Two-part 0.77 0.14 0.36 1 0.0156 0.0933
Model 2e. Beta QMLE 0.77 0.15 0.20 0.95 0.0146 0.0918
Model 2f. Finite mixture model 0.77 0.17 0.24 1 0.0171 0.0871
External validation sample (n = 1152)
Observed EQ-5D-3L 0.90 0.12 0.20 1 — —
Model 2a. OLS 0.88 0.12 0.49 1.03 0.0087 0.0685
Model 2b. OLS (+ squared) 0.87 0.10 0.40 0.98 0.0085 0.0731
Model 2c. OLS (+ squared + interaction) 0.87 0.10 0.42 1.02 0.0083 0.0729
Model 2d. Two-part 0.88 0.12 0.49 1 0.0088 0.0682
Model 2e. Beta QMLE 0.87 0.09 0.42 0.95 0.0085 0.0772
Model 2f. Finite mixture model 0.88 0.13 0.31 1 0.0100 0.0567
Note: EQ-5D-3L = EuroQol Five-Dimension Three-Response Levels survey; MOS-HIV = Medical Outcomes Study HIV Health Survey; MSE = mean
squared error; MAE = mean absolute error; OLS = ordinary least squares; Beta QMLE = beta regression based on quasi likelihood estimation.
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terms model (Table 2, Model 1b); the online supple-
ment calculates EQ-5D-3L scores from the finite
mixture model estimates (Table 2, Model 2f).
HUI3 = –0.439103 + (0.001869*GeneralHealth
Perception) + (0.007183*Pain) +
(0.001779*QualityOfLife) +
(0.000156*RoleFunctioning) +
(0.003304*SocialFunctioning) +
(0.002787*EnergyFatigue) +
(0.002948*MentalHealth) +
(–0.001440*HealthDistress) +
(0.003267*CognitiveFunctioning) +
(0.000591*PhysicalFunctioning) +
(–0.000015*GeneralHealthPerception_sq) +
(–0.000037*Pain_sq) +
(–0.000005*QualityOfLife_sq) +
(0.000005*RoleFunctioning_sq) +
(–0.000020*SocialFunctioning_sq) +
(–0.000016*EnergyFatigue_sq) +
(–0.000012*MentalHealth_sq) +
(0.000008*HealthDistress_sq) +
(0.000006*CognitiveFunctioning_sq) +
(0.000004*PhysicalFunctioning_sq)
DISCUSSION
In accordance with the MAPS statement,32,33 we
developed and compared the performance of several
regression models mapping MOS-HIV dimension
scores onto HUI3 or EQ-5D-3L utility values. The
OLS model with squared terms (1b) is the preferred
model with the best goodness of fit (MAE 0.0961)
among the HUI3 mapping models; the finite mixture
model (2f) is the preferred model among the EQ-5D-
3L mapping models with a MAE of 0.0567. To our
knowledge, this study is the first to map the MOS-
HIV onto the HUI3.
Previous mapping models have reported MAEs at
the individual level ranging from 0.0011 to 0.1917;
the models presented here performed well within
that range with external validation MAEs ranging
from 0.0567 (EQ-5D-3L, Model 2f) to 0.1040 (HUI3,
Model 1a). We also found that, similar to other map-
ping studies, there was considerable mean absolute
error variation across the range of either HUI3 or
EQ-5D-3L index scores. This phenomenon has been
found in previous studies.16,17 Hawton and oth-
ers,16 for example, mapped the Multiple Sclerosis
Impact Scale onto the EQ-5D-3L and found that
MAEs for predicted utility value scores increased as
EQ-5D-3L scores decreased, with MAE values
greater than 0.25 for EQ-5D-3L utility values less
than 0.249. It is important to note that variation in
MAE at the lower end of the range may be related to
smaller sample sizes. Only 5.4% of all of the EQ-
5D-3L values collected in the validation sample fell
below 0.40.
To date, only Huang and others24 have mapped
the MOS-HIV onto the EQ-5D-3L. Their preferred
models included a latent class model and a two-
part model with a log-transformed dependent vari-
able. We were unable to compare model perfor-
mance since the authors did not report estimates of
mean absolute error or mean standard error and did
not report the parameters for the intercept needed
to apply the mapping algorithms to our external vali-
dation data set. However, in comparing parameter
estimates from Huang’s basic OLS model and our
basic OLS model (2a), we found that physical func-
tioning, pain, health distress, and mental health
were all statistically significant predictors for both
models. Differences between our mapping algo-
rithms may be explained by the fact that Huang’s
cohort was younger, had a slightly higher mean base-
line CD4 cell count, and was less racially diverse
than the OPTIMA sample used to derive our map-
ping algorithm. The percentage of EQ-5D-3L scores
at the ceiling may also play a part; over 40% of
patients had the maximum EQ-5D-3L score of 1 in
Huang’s cohort compared to just 22% in OPTIMA.
Our study had several limitations. First, we did
not include sociodemographic or clinical variables
into any of our models. Including these variables
would control for more factors that would influence
quality of life; however, it would also restrict the
application of our mapping algorithms to only those
trials that recorded the same information along with
the MOS-HIV. However, adding basic sociodemo-
graphic characteristics such as age may allow for
the fact that measures of HRQoL often do not per-
form equally across different age groups. Second,
we applied US tariffs when calculating EQ-5D-3L
scores regardless of the country of origin for the
individual quality of life surveys in the estimation
and validation data sets. Most scores (78%) in our
estimation sample came from US study partici-
pants. Choosing a single tariff allowed us to focus
on internal validity, despite the loss of some gener-
alizability. We expect the mappings to behave simi-
larly for other tariffs, but we leave this topic to
future research. Finally, we found that predictions
were less accurate at the lower range of EQ-5D-3L
utility values. These problems may limit the applic-
ability of this mapping algorithm for studies with
cohorts in very poor health.
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Regardless of the HIV cohort, prospective direct
or indirect elicitation of utility values is important
and is preferred to mapped utility values as it
avoids introducing additional uncertainty into the
estimates.30 However, when preference-based meth-
ods are not feasible or not available, our externally
validated mapping algorithms allow clinicians and
researchers to obtain reliable estimates of mean
HUI3 and EQ-5D-3L scores from studies that only
collected the MOS-HIV. These predicted utility val-
ues can be useful in populating health states in eco-
nomic models.
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